Private health plans in Canada continue to implement many changes in their design and use of technology aimed at balancing … Read More
In December 2017, the Governor-in-Council published in Canada Gazette Part 1 the most comprehensive changes affecting patented medicines since Bill … Read More
The release of the Patented Medicine Prices Review Board (PMPRB) Annual Report is delayed once again this year – so … Read More
Owing to new developments and growing stakeholder interest, PDCI and H3 have now completed a second private payer PLA survey. … Read More
PHARMACARE COSTING IN CANADA Estimated Costs of Proposed National Pharmacare Programs.
Full report available here.
The objective of this preliminary report is to summarize PDCI’s assessment of the national pharmacare cost estimate study (Morgan et … Read More
Report 4: PLA Perspectives, Comparison and Contrast
Last week Manulife introduced its new DrugWatch™. It has been described by Manulife … Read More
Report 3: Experience Negotiating Private Payer PLAs
PDCI Market Access (PDCI) and H3 Consulting (H3) recently launched the Private Payer Product … Read More